Mesoblast Financial Results and Corporate Update
Mesoblast Limited (NASDAQ: MESO; ASX: MSB) is leading the way in developing allogeneic cellular therapies aimed at treating inflammatory diseases. The company will host a webcast to share its operational highlights and financial results for the year ending June 30, 2024.
Webcast Details
The webcast is set to start at 6:30 PM EDT, providing a comprehensive overview of the company’s achievements over the past fiscal year. Tune in to gain insights into Mesoblast’s performance and growth metrics.
Mesoblast's Innovations in Cellular Medicine
Mesoblast has positioned itself as a pioneer in allogeneic (off-the-shelf) cellular treatments for serious inflammatory conditions. Their proprietary mesenchymal lineage cell therapy technology plays a crucial role in their diverse portfolio, which features several late-stage product candidates. These therapies aim to combat severe inflammation by releasing anti-inflammatory agents, effectively modulating the immune system's response to minimize the harmful effects of inflammation.
Global Intellectual Property and Manufacturing Capabilities
The company boasts a strong global intellectual property portfolio that offers protection until at least 2041 in all major markets. Mesoblast's unique manufacturing processes enable the production of industrial-scale, cryopreserved cellular medicines that are readily available for patients worldwide.
Development of Distinct Product Candidates
Mesoblast is advancing multiple product candidates utilizing its innovative remestemcel-L and rexlemestrocel-L platforms. Remestemcel-L is designed to treat inflammatory diseases in both children and adults, particularly conditions such as steroid-refractory acute graft versus host disease and biologic-resistant inflammatory bowel disease. On the other hand, rexlemestrocel-L focuses on advanced chronic heart failure and chronic low back pain. Some of these products have already been launched in Japan and Europe through strategic partnerships.
Commercial Partnerships and Future Outlook
The company is actively forming commercial partnerships in Europe and China to propel its Phase 3 assets forward. With its extensive network and innovative strategies, Mesoblast is well-positioned to make significant strides in the global cellular therapy market.
Company Overview and Contact Information
With operational hubs in Australia, the United States, and Singapore, Mesoblast is publicly traded on both the Australian Securities Exchange (ASX: MSB) and the Nasdaq (NASDAQ: MESO). The company is dedicated to advancing its groundbreaking cellular medical technologies and expanding its market presence.
For more information, please contact:
Corporate Communications / Investors:
Paul Hughes
T: +61 3 9639 6036
E: investors@mesoblast.com
Media:
Steve Dabkowski
T: +61 419 880 486
E: steve@bluedot.net.au
Frequently Asked Questions
What is the purpose of the Mesoblast webcast?
The webcast aims to present operational highlights and the financial results of Mesoblast for the fiscal year ending June 30, 2024.
What are the key product platforms developed by Mesoblast?
Mesoblast's primary product platforms are remestemcel-L and rexlemestrocel-L, which focus on treating severe inflammatory conditions and other critical diseases.
Where can I find archived information about the webcast?
Archived information about the webcast will be available on Mesoblast's Investor page once it is released.
What markets are Mesoblast's products targeting?
Mesoblast targets major global markets, including regions in Asia, Europe, and North America, with a focus on severe inflammatory conditions.
How can I contact Mesoblast for more information?
For inquiries related to corporate communications or investors, you can reach Paul Hughes at +61 3 9639 6036 or email at investors@mesoblast.com.
